Compare IVVD & ICCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IVVD | ICCM |
|---|---|---|
| Founded | 2020 | 2006 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 692.7M | 45.5M |
| IPO Year | 2021 | N/A |
| Metric | IVVD | ICCM |
|---|---|---|
| Price | $2.27 | $0.69 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $8.33 | $2.50 |
| AVG Volume (30 Days) | ★ 12.0M | 403.0K |
| Earning Date | 11-06-2025 | 11-19-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $50,039,000.00 | $2,975,000.00 |
| Revenue This Year | $103.88 | $13.67 |
| Revenue Next Year | $171.40 | $38.55 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 332.71 | N/A |
| 52 Week Low | $0.35 | $0.59 |
| 52 Week High | $3.07 | $1.66 |
| Indicator | IVVD | ICCM |
|---|---|---|
| Relative Strength Index (RSI) | 53.98 | 41.99 |
| Support Level | $2.09 | $0.67 |
| Resistance Level | $2.60 | $0.72 |
| Average True Range (ATR) | 0.22 | 0.05 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 17.86 | 62.50 |
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.